Yann Gaston-Mathe

Digital

Yann Gaston-Mathe, founder and CEO of Iktos, discusses AI drug discovery's shift to real-world operations that are able to incorporate wet lab data.

News

Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.

Sales & Marketing

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.